Loading...

BioLargo

OTCPK:BLGO
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BLGO
OTCPK
$26M
Market Cap
  1. Home
  2. US
  3. Materials
Company description

BioLargo, Inc. operates as a science, technology, and environmental engineering company. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
BLGO Share Price and Events
7 Day Returns
6.8%
OTCPK:BLGO
1.1%
US Chemicals
0.2%
US Market
1 Year Returns
-28.4%
OTCPK:BLGO
-13.8%
US Chemicals
2.9%
US Market
BLGO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioLargo (BLGO) 6.8% 3.7% -9.3% -28.4% -54.6% -74.1%
US Chemicals 1.1% -6.2% -9.4% -13.8% 15.3% 6.5%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • BLGO underperformed the Chemicals industry which returned -13.8% over the past year.
  • BLGO underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
BLGO
Industry
5yr Volatility vs Market

Value

 Is BioLargo undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether BioLargo is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioLargo has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioLargo. This is due to cash flow or dividend data being unavailable. The share price is $0.1815.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioLargo's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioLargo's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:BLGO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.08
OTCPK:BLGO Share Price ** OTCPK (2019-05-22) in USD $0.18
United States of America Chemicals Industry PE Ratio Median Figure of 67 Publicly-Listed Chemicals Companies 17.93x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioLargo.

OTCPK:BLGO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:BLGO Share Price ÷ EPS (both in USD)

= 0.18 ÷ -0.08

-2.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLargo is loss making, we can't compare its value to the US Chemicals industry average.
  • BioLargo is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BioLargo's expected growth come at a high price?
Raw Data
OTCPK:BLGO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Chemicals Industry PEG Ratio Median Figure of 49 Publicly-Listed Chemicals Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioLargo, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioLargo's assets?
Raw Data
OTCPK:BLGO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.01
OTCPK:BLGO Share Price * OTCPK (2019-05-22) in USD $0.18
United States of America Chemicals Industry PB Ratio Median Figure of 93 Publicly-Listed Chemicals Companies 2.05x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
OTCPK:BLGO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:BLGO Share Price ÷ Book Value per Share (both in USD)

= 0.18 ÷ -0.01

-12.4x

* Primary Listing of BioLargo.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioLargo has negative assets, we can't compare the value of its assets to the US Chemicals industry average.

Next steps:

  1. Take a look at our analysis of BLGO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Chemicals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess BioLargo's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. BioLargo has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioLargo expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioLargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected Chemicals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioLargo expected to grow at an attractive rate?
  • Unable to compare BioLargo's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BioLargo's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare BioLargo's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:BLGO Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
United States of America Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:BLGO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:BLGO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -4 -10
2018-12-31 1 -4 -10
2018-09-30 1 -4 -10
2018-06-30 1 -4 -10
2018-03-31 1 -4 -9
2017-12-31 1 -4 -9
2017-09-30 0 -4 -9
2017-06-30 0 -4 -9
2017-03-31 0 -4 -9
2016-12-31 0 -4 -8
2016-09-30 0 -3 -7
2016-06-30 0 -3 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BioLargo is high growth as no earnings estimate data is available.
  • Unable to determine if BioLargo is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:BLGO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BioLargo Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BLGO Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.08
2018-12-31 -0.08
2018-09-30 -0.09
2018-06-30 -0.10
2018-03-31 -0.09
2017-12-31 -0.09
2017-09-30 -0.09
2017-06-30 -0.10
2017-03-31 -0.09
2016-12-31 -0.09
2016-09-30 -0.08
2016-06-30 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioLargo will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BLGO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. BioLargo's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Materials companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioLargo's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BioLargo's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioLargo has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioLargo performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioLargo's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioLargo does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioLargo's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioLargo's 1-year growth to the US Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
BioLargo's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioLargo Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BLGO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.47 -10.48 5.49 1.62
2018-12-31 1.36 -10.22 5.26 1.72
2018-09-30 1.06 -10.39 4.95 1.88
2018-06-30 0.96 -10.28 4.70 1.86
2018-03-31 0.73 -9.18 4.54 1.76
2017-12-31 0.52 -9.12 4.43 1.63
2017-09-30 0.38 -9.05 4.21 1.49
2017-06-30 0.37 -9.31 4.08 1.42
2017-03-31 0.31 -8.52 3.84 1.42
2016-12-31 0.28 -7.84 3.71 1.38
2016-09-30 0.27 -6.86 3.52 1.25
2016-06-30 0.15 -6.26 3.99 1.06
2016-03-31 0.13 -5.85 3.92 0.90
2015-12-31 0.13 -5.06 3.55 0.68
2015-09-30 0.14 -4.55 3.46 0.63
2015-06-30 0.11 -3.56 2.66 0.66
2015-03-31 0.12 -3.45 2.75 0.62
2014-12-31 0.11 -3.69 2.79 0.64
2014-09-30 0.06 -3.59 2.74 0.62
2014-06-30 0.06 -3.47 2.63 0.70
2014-03-31 0.16 -2.90 2.08 0.79
2013-12-31 0.17 -2.53 2.00 0.74
2013-09-30 0.16 -3.60 2.95 0.68
2013-06-30 0.16 -3.82 3.18 0.53
2013-03-31 0.05 -5.06 4.18 0.49
2012-12-31 0.07 -5.33 4.35 0.38
2012-09-30 0.07 -4.52 3.58 0.36
2012-06-30 0.18 -4.32 3.40 0.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioLargo has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if BioLargo has efficiently used its assets last year compared to the US Chemicals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioLargo improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioLargo's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioLargo has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioLargo's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioLargo's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioLargo's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BioLargo's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of BioLargo's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioLargo has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioLargo Company Filings, last reported 1 month ago.

OTCPK:BLGO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -1.79 3.88 0.51
2018-12-31 -1.12 3.16 0.66
2018-09-30 -0.98 1.71 0.53
2018-06-30 -0.64 1.56 0.65
2018-03-31 -4.62 5.72 0.92
2017-12-31 -3.41 4.68 0.99
2017-09-30 -2.40 3.69 1.25
2017-06-30 -3.48 3.15 0.43
2017-03-31 -1.62 2.49 1.18
2016-12-31 -0.77 1.94 1.91
2016-09-30 -0.16 1.50 1.73
2016-06-30 -0.43 1.04 0.89
2016-03-31 0.22 0.62 1.02
2015-12-31 1.14 0.31 1.76
2015-09-30 0.26 0.11 0.56
2015-06-30 -0.49 0.21 0.10
2015-03-31 -0.41 0.13 0.23
2014-12-31 -0.39 0.06 0.15
2014-09-30 -0.33 0.05 0.15
2014-06-30 -0.05 0.05 0.32
2014-03-31 -0.02 0.05 0.36
2013-12-31 -0.56 0.33 0.09
2013-09-30 -0.36 0.10 0.05
2013-06-30 -0.57 0.10 0.07
2013-03-31 -0.48 0.10 0.09
2012-12-31 -0.29 0.10 0.15
2012-09-30 -1.05 0.50 0.43
2012-06-30 -0.94 0.48 0.52
  • BioLargo has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if BioLargo's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioLargo has less than a year of cash runway based on current free cash flow.
  • BioLargo has less than a year of cash runway if free cash flow continues to grow at historical rates of 11% each year.
X
Financial health checks
We assess BioLargo's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioLargo has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioLargo's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioLargo dividends.
If you bought $2,000 of BioLargo shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioLargo's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioLargo's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:BLGO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 54 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioLargo has not reported any payouts.
  • Unable to verify if BioLargo's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioLargo's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioLargo has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioLargo's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioLargo afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioLargo has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioLargo's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dennis Calvert
COMPENSATION $655,748
AGE 55
TENURE AS CEO 16.9 years
CEO Bio

Mr. Dennis P. Calvert serves as the Chairman of the Board at BioLargo, Inc. and has been its Chief Executive Officer and President since June 28, 2002. Mr. Calvert has an extensive entrepreneurial background as an operator, investor and Consultant. He also serves as President, Chief Executive Officer and Chairman BioLargo Life Technologies, Inc. and BioLargo Water U.S.A., Inc. and chairman of the board of directors of Odor-No-More, Inc., Clyra Medical Technologies, Inc. and BioLargo Water, Inc. (Canada). He served as Interim Chief Financial Officer of BioLargo, Inc. since March 2003, Chief Financial Officer from March 2003 to January 2008 and as its Corporate Secretary from September 12, 2002 to March 1, 2003. From June 2002 to September 2002, he served as President of Med Wireless, Inc. In 1998, Mr. Calvert founded Utelecom Communications, Inc. and served as its President, where he led the acquisition of four companies and secured a line of credit for $7.5 million dollars. He served as a Manager of Beep of Free.com, LLC since 2000. From 1990 to 1996, he served as Head of Mergers and Acquisitions of Medical Asset Management, Inc. During his tenure, he participated in more than 50 acquisitions and served in numerous positions with Medical Asset Management, Inc. Mr. Calvert founded Merritt Hawkins and Associates and served as its Officer from 1987 to 1990. Earlier, he served as Top Producing Sales Associate of Jackson and Coker, Inc. and served as a Sales Associate of Diamond Shamrock Chemicals Company from 1985 to 1986. Mr. Calvert founded ZZYZX Technologies, Inc. and served as its Chairman. He has been a Director of Utelecom Communications, Inc. since 1998 and BioLargo, Inc. since June 28, 2002. He also serves on the board of directors at The Maximum Impact Foundation. He serves as a member of the Advisory Council for Wake Forest University’s Center for Innovation, Creativity and Entrepreneurship, and as a Director of Cleantech OC. He joined the Board of Directors of Tilly’s Life Center. He is also an Eagle Scout. He has been an active coach in youth sports organizations and ministry activity in his home community. Mr. Calvert holds a BA degree in Economics from Wake Forest University, where he was a varsity basketball player on full scholarship. He studied at Columbia University and Harding University. He was an honor student in high school with numerous leadership awards.

CEO Compensation
  • Dennis's compensation has increased whilst company is loss making.
  • Dennis's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioLargo management team in years:

11.3
Average Tenure
59
Average Age
  • The average tenure for the BioLargo management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Dennis Calvert

TITLE
President
COMPENSATION
$656K
AGE
55
TENURE
16.9 yrs

Charles Dargan

TITLE
Chief Financial Officer
COMPENSATION
$88K
AGE
63
TENURE
11.3 yrs

Joe Provenzano

TITLE
VP of Operations
COMPENSATION
$224K
AGE
49
TENURE
11.3 yrs

Kenneth Code

TITLE
Chief Science Officer & Director
COMPENSATION
$301K
AGE
71
Board of Directors Tenure

Average tenure and age of the BioLargo board of directors in years:

9.9
Average Tenure
58
Average Age
  • The tenure for the BioLargo board of directors is about average.
Board of Directors

Dennis Calvert

TITLE
President
COMPENSATION
$656K
AGE
55

Joe Provenzano

TITLE
VP of Operations
COMPENSATION
$224K
AGE
49
TENURE
16.9 yrs

Kenneth Code

TITLE
Chief Science Officer & Director
COMPENSATION
$301K
AGE
71
TENURE
12.1 yrs

Dennis Marshall

TITLE
Independent Director
COMPENSATION
$75K
AGE
75
TENURE
13.1 yrs

John Runyan

TITLE
Independent Director
COMPENSATION
$75K
AGE
79
TENURE
7.6 yrs

Rick Roberts

TITLE
Independent Director
COMPENSATION
$60K
AGE
58
TENURE
7.8 yrs

Jack Strommen

TITLE
Director
COMPENSATION
$60K
AGE
48
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess BioLargo's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioLargo has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioLargo, Inc. operates as a science, technology, and environmental engineering company. Its platform technologies include Advanced Oxidation System (AOS), CupriDyne, and Isan. The company offers odor and volatile organic compound control products, AOS water treatment technologies, and technologies in the medical and dental fields, as well as professional engineering services. It provides commercial, household, and personal care products, including an animal-bedding additive that controls odor and moisture; and liquid odor control products under the Odor-No-More, Nature’s Best Science, Deodorall, and NBS brand names. BioLargo, Inc. was founded in 1989 and is based in Westminster, California.

Details
Name: BioLargo, Inc.
BLGO
Exchange: OTCPK
Founded: 1989
$26,308,980
144,953,058
Website: http://www.biolargo.com
Address: BioLargo, Inc.
14921 Chestnut Street,
Westminster,
California, 92683,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK BLGO Common Stock Pink Sheets LLC US USD 01. May 2007
Number of employees
Current staff
Staff numbers
25
BioLargo employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 05:34
End of day share price update: 2019/05/22 00:00
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.